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Aluminum localization in bone from hemodialyzed patients: Relation-
ship to matrix mineralization. It has been suggested that in uremic bone,
aluminum interferes with normal mineralization. Aluminum content and
aluminum localization were studied in iliac crest biopsies of two groups
of patients on regular hemodialysis; one group had histologic osteolna-
lacia, and little or no bone resorption (group 1); the other, osteitis
fibrosa and no mineralization defect (group 2). Group I patients had
significantly higher plasma aluminum concentrations than those of
group 2. No difference was found in bone aluminum content, which was
above normal in both groups. In the bone samples of the osteomalacic
subjects, aluminum was mainly localized at the limit between osteoid
and calcified tissue, the site where the bone mineral is normally first
deposited. Osteomalacia could not be related to hypocalcemia or to
phosphate depletion. Active vitamin D derivatives (25-hydroxychole-
calciferol and lix-hydroxycholecalciferol) failed to prevent or to im-
prove the bone disease. In the bone samples of group 2 subjects,
aluminum could not be localized by the methods used, except in the two
cases with greatly elevated bone aluminum, where it was mainly
localized on cement lines. In group 2 subjects, immunoreactive parathy-
roid hormone plasma concentrations, osteoclast surface, and marrow
fibrosis were significantly higher than they were in group I subjects. It
is concluded that in bone from uremic patients on regular dialysis,
aluminum can induce a particular form of osteomalacia, resistant to the
vitamin D active derivatives. The bone disease is only observed in the
absence of severe secondary hyperparathyroidism. This suggests that
parathyroid hormone may be involved in the development of the
aluminum-induced mineralization defect.
Localisation de l'aluminium dans le tissu osseux de malades en hémo-
dialyse periodique: Relation avec Ia mineralisation de Ia matrice. L'hy-
pothèse que l'aluminium influence Ia mineralisation dans le tissu osseux
de malades urémiques a été récemment avancée. Dans ce travail Ia
teneur en aluminium et Ia localisation de l'aluminium ont été étudiées
dans les biopsies osseuses de deux groupes de malades hemodialysés.
Un groupe avait des signes histologiques d'ostéomalacie, Ia resorption
étant absente ou peu prononcée (groupe I), l'autre des lesions plus ou
moms importantes d'ostCite fibreuse, sans troubles de La mineralisation
(groupe 2). L'aluminémie des malades du groupe 1 était significative-
ment supCrieure a celle des malades du groupe 2; aucune difference
n'existait dans Ia teneur en aluminium de l'os, qui dans les deux groupes
était supérieure a Ia normale. Dans le tissu osseux des malades
osteomalaciques l'aluminium était principalement concentré a Ia limite
entre tissu minéralisé et tissu ostéoide, a l'endroit oO normalement Ia
matrice organique se minéralise. Les lesions n'étaient pas dues a une
carence en calcium ou a une déplétion en phosphore. Les dérivés actifs
de Ia vitamine D (25-hydroxycholCcalciférol et lct-hydroxycholecalci-
férol) n'ont pas amelioré l'ostéomalacie ou empêché son apparition.
Dans Ic tissu osseux des malades du groupe 2 l'aluminium n'a Pu étre
localisé, sauf chez deux malades dont Ia concentration osseuse en
aluminium Ctait très élevée. Chez ces deux malades l'aluminium était
principalement situé Ic long des lignes cementantes. La concentration
plasmatique de l'hormone parathyroIdienne immunorCactive, Ia surface
osteoclastique et Ia fibrose médullaire des malades du groupe 2 étaient
significativement supérieures a celles des malades du groupe 1. En
conclusion, chez des malades hemodialyses, l'aluminium peut entrainer
une forme particuliere d'ostéomalacie qui résiste aux dérivés actifs de Ia
vitamine D. Cette ostéomalacie ne s'observe qu'en l'absence d'hyper-
parathyroIdie secondaire importante; l'hormone parathyroidienne pour-
rait done jouer un role dans le dévelopement de l'ostéomalacie par
intoxication a I'aluminium.
In advanced renal failure, histologic bone disease is present
in nearly all patients. The main lesions are osteitis fibrosa and
osteomalacia. Osteitis fibrosa is due to secondary hyperpara-
thyroidism, which increases the bone turnover. The histologic
changes are an increase in the number of active bone cells,
osteoblasts, and osteoclasts, the formation of woven bone, and
the presence of marrow fibrosis. The amount of osteold tissue
may be high as a result of osteoblast activity, but the mineral-
ization front is not reduced. In contrast, osteomalacia is charac-
terized by decreased mineralization front, wide osteoid seams,
and increased osteoid volume. These changes indicate a defect
in the mineralization of the organic matrix.
The pathogenesis of the osteomalacic lesions is complex; the
main causes are a deficiency of the active vitamin D metabolites
[1], and phosphate depletion [2]. In children, rickets have also
been attributed to calcium deficiency [3, 4]. Recently, it has
been suggested [5—7] that, in subjects on regular hemodialysis,
osteomalacia can also be induced by aluminum intoxication,
often associated with a syndrome of dialysis dementia, first
described by Aifrey, Le Gendre, and Kaehny [8]. This hypothe-
sis is supported by the fact that, in these patients, the incidence
of both osteomalacia and encephalopathy correlates with the
aluminum content of the water used to prepare the dialysate.
Furthermore, it has been shown that the aluminum retained
during dialysis, as well as the aluminum absorbed from the
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Table 1. Clinical, radiologic, and treatment data of the two groups of patients before bone biopsya
phosphate binders prescribed to control serum phosphorus
levels, accumulates in bone [9—121. In rats given aluminum
chloride, bone aluminum is elevated and osteomalacia develops
113].
All these observations provide indirect evidence that alumi-
num intoxication may induce osteomalacic lesions. But, the
direct relationship between aluminum and mineralization has
not yet been demonstrated, and the precise localization of
aluminum in bone tissue is not known. This localization would
be of great interest to determine if aluminum really does
interfere directly with the mineralization process.
The purpose of the present work was to study aluminum
localization and aluminum content in the bone biopsies of a
group of uremic patients on regular hemodialysis with histologic
osteomalacia and little or no bone resorption. For comparison,
a second group of dialyzed patients with histologic osteitis
fibrosa and no mineralization defect was studied.
Methods
Patients. The main clinical, radiologic, and therapeutic data
of the two groups of patients are indicated in Table 1. The
patients were selected according to the following criteria:
radiologic osteomalacia and/or suspicion of aluminum intoxica-
tion and skeletal lesions of osteitis fibrosa.
Group 1. Patients with osteomalacia and little or no bone
resorption. Three patients in this group showed symptoms of
dialysis encephalopathy, such as dysartria, aphasia, personality
changes, and typical electroencephalogram abnormalities [14];
less characteristic symptoms were seen in two patients, and no
such symptoms were present in the others. In Table 1 the
severity of these symptoms is indicated from (+) to + + +. Two
patients (patients 4 and 11) underwent subtotal parathyroidecto-
my 9 and 30 months prior to bone biopsy, respectively. Six
patients were treated by active vitamin D derivatives. Dialysis
was performed for 12 to 16 hours weekly on a 1-rn2 dialyzer
equipped with a polyacrylonitrile membrane for patients 1, 2,
and 7, and with a cuprophane membrane for the others.
Calcium dialysate concentration was 1.75 mmoles/liter except
in patient 8, who was dialyzed with a fluid containing 1.5
mmoles/liter. For all patients, softened water was used for
dialysate preparation.
Group 2: Patients with moderate to severe osteitis fibrosa.
The electroencephalogram abnormalities of patient 12 showed
the characteristic pattern observed in dialysis encephalopathy.
This subject developed clinical symptoms during the months
following the bone biopsy. Five patients received active vitamin
D derivatives. Dialysis was performed for 12 to 16 hours weekly
on a 1-rn2 dialyzer, equipped with a polyacrylonitrile mem-
No.
Patient Duration
dialysis
of
Age
yr Sex Diagnosis yr mo Bone pain Osteitis fibrosa
Radiology
Osteomalacia
Group I
1 33 F CPN 2 6 + 0 +
2 31 M CGN 9 8 + 0 ++
3 48 M CGN 3 4 + 0 +
4 50 M CGN 8 — + 0 +
5 51 M Polycystic disease 5 9 + 0 ++
6 34 M CGN 10 — + 0 +
7 51 M Polycystic disease 3 — + (+) ++
8 47 F Polycystic disease 2 — + 0 +
9 42 F CPM 3 9 0 0 0
10 35 M CGN 3 6 + (+) 0
11 41 M Unclassified 9 — + (+) 0
Mean 42 5 6
12 56 M Familial nephropathy
Group 2
5 6 0 (+) 0
13 49 M CGN 9 7 + +++ 0
14 42 F CPN 5 2 0 +++ 0
15 35 F Unclassified 2 3 0 ++ 0
16 57 M CGN 5 — 0 (+) 0
17 45 F CPN 7 3 + ++ 0
18 51 F CPN 9 8 0 +++ 0
19 41 M Polycystic disease 6 8 0 + 0
20 58 F Polycystic disease 5 8 + + 0
21 41 M CGN 5 — 0 + 0
Mean 47.5 7 1
a Symbols are defined in text. CPN is chronic pyelonephritis; CGN, chronic glomerulonephritis; EEG, electroencephalogram; 25-(OH)D3, 25-
hydroxycholecalciferol; lcs-(OH)D3, lcs-hydroxycholecalciferol; H, home dialysis; (0), dialysis fluid prepared with deionized water during the year
preceding bone biopsy; the aluminum content of the softened water used during the years before is not known.
b Elemental aluminum content of the phosphate binders prescribed during the year before the biopsy.
Mean SEM (N = 19) during 18 months prior to biopsy.
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Table 1. (con't.)
Neurology
Therapy
25-(OH)D3
Dose Duration
la-(OH)D3
Aluminum orally'
Aluminum
content of
dialysis fluidDose Duration
Encephalopathy Abnormal EEG p.g/day mo iig/day ma glyr p.g/liter
Group 1
(+) (+) — — — — 360 5—310
0 — 50 4 1—0.3 12 2000 10— 30
+ ÷ 25 9 — — 1000 30H
+ + — — 1—0.3 9 650 53—175 H
0 — 40—75 23 — — 200 120 H
0 0 15 6 — — 350 120H
0 (+) — — — — 450 96 18c
0 — — — — — 1800 —
+++ +++ 25—50 14 — — 400 250H
0 — — — — — 1200 150H
0 — 100 12 — — — —
Group 2
0 + — — — — 600 96±18c
0 (+) 50 0.5 — — 400
0 0 — — — — 1700 20H
0 — 100 20 1 2 400 10— 20
0 — — — — — 700 (0)
0 — 50—75 16 — — 900 (0)
0 — — — 0.5 1 800 0
0 — 100 8 1 4 800 6—20(+) (+) 25 12 — — 900 (0)
0 — — — — — 1500 (0)
brane for patients 12, 18, 19, and 20, and with a cuprophane
membrane for the others. Softened water was used for dialysate
preparation in all cases, except in patient 18, who used deion-
ized water.
Radiology. Osteitis fibrosa lesions were classified as follows
(Table 1): (+) and + denotes granular rarefaction of the vault of
the skull and/or mild subperiosteal erosions of phalanges; + +,
evident and numerous subperiosteal erosions of phalanges and
erosion of the distal extremity of claviculae; + + +, partial
dissolution of terminal phalanges and multiple cystic rarefac-
tions, subperiosteal cortical erosions of claviculae. For osteo-
malacic lesions, only Looser's zones and pseudofractures have
been regarded as pathognomonic. The severity of the lesions
was classified as + (one pathologic fracture and/or Looser's
zones) and + + (multiple pathologic fractures).
Plasma biochemistry. In all patients, blood samples were
obtained immediately before dialysis. Plasma calcium and phos-
phorus were measured by autoanalyzer SMA 12-60 (Technicon,
Domont, France); plasma alkaline phosphatase, according to a
kinetic method [15], except for patients, 3, 4, 6, 7, 19, and 21.
Because, in these cases, measurements were performed in
different laboratories with different techniques, the following
symbols were used, for interpretation purposes: N denotes
normal; (+), 50% increase; ++, 200% increase in plasma
alkaline phosphatases activities. Plasma immunoreactive para-
thyroid hormone (iPTH) was measured by a modification of the
method of Arnaud, Tsao, and Littledike [16]. The antibody used
(chicken antibovine PTH) predominantly detects the carboxy-
terminal fragments, and values are expressed as equivalents of
purified bovine PTH. The lower limit of detection is 0.1 ng/ml;
normal values are lower or equal to 0.5 ng/ml. 25-Hydroxyvita-
mm D (25-(OH)D) plasma levels were measured by a competi-
tive protein assay using a rat serum as binding protein [17].
Aluminum was measured by flameless atomic absorption. [181.
Bone studies. Bone biopsies were obtained from the anterior
iliac crest with the trepine of Bordier. From each fresh sample,
a small piece (around 50 mg) of mainly cortical bone was taken
for aluminum analysis. The remaining part of the sample was
prepared for histologic examination. Bone aluminum was deter-
mined with the same technique as plasma aluminum. Values are
expressed in micrograms per gram of fresh tissue.
Histology and morphometry. The biopsies were fixed in 90%
alcohol or in a mixture of formaldehyde and glutaraldehyde, and
embedded in methylmethacrylate or epon without decalcifica-
tion. The water used for histologic processing was controlled,
deionized water. Five-micron-thick sections were cut with a
Jung K microtome and stained with toluidine blue (pH 6.4) or
eosine-azur. Morphometric data were obtained with Zeiss inte-
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Table 2. Aluminum content and bone morphometry of the two groups of patients.
Morphometry"
Osteoid volume
Bone •Osteoid Mineraliza- Mean seam Osteoblast Osteoclast Marrow
Al volume Relative Total surface tion front thickness surface surface fibrosis
Patient no. p.glg % % % % % % %
1 51 28.7 32.7 9.3
Group /
74.5 4.1 18.8 0.4 0.2 0
2 130 37.9 27 10.3 — 13.9 — — (+) 0
3 57 18 23.8 4.7 72 16 14.7 1.35 1.3 0.1
4 67 23 18.3 4.2 76 6.2 16.4 0 0. 0
5 56.5 20.6 19.8 4 69.5 4 16 0 0.2 0
6 94 36 19.6 7 61.5 15.8 26.2 1.8 3.6 0
7 25 9.6 19.5 1.9 71.4 6.4 13.3 6.4 1.5 0.3
8 19.5 34.5 5.4 1.8 28 14.4 13 0 0 0
9 84 44.9 21.3 9.6 80.8 12.6 19.4 0 0.7 0
10 12 18.4 13.2 2.4 42.9 4.2 18.9 0 2.4 0.2
11 20 17.4 7.6 1.3 24.5 37.3
Group 2
14.5 4.9 1.3 0.4
12 100 27.4 4.8 1.3 34.6 53 9.7 8.8 4.4 1.5
13 112 50.6 21.9 11 61.8 61.3 24.7 10.3 7.5 5.7
14 40 35.2 13.9 4.9 59.5 78.1 12.5 41 6.4 62.7
15 62 36.2 18.8 6.8 60.2 61.6 11.9 17.9 6.2 7.9
16 15 25.3 2.2 0.6 17.2 68.9 8.2 5.2 2.9 1
17 31 35.2 16 5.6 54.1 67.1 16.1 31.8 5.7 12.7
18 38 21.2 5.9 1.3 41.5 82 10.4 15.4 8.2 3.5
19 4 16.2 2.7 0.4 20.5 54 10.5 4.5 3.5 0.6
20 25.2 28.4 6.3 1.8 20.9 67 12.3 16.5 5.1 11.9
21 35 25.9 10.6 2.7 57.3 65.9 13.8 13.7 5.9 4
Normal valuesb < 8 21 5 1.1 13.9 63.3 10 4.7 0.53 0
P" NS NS < 0.05 NS < 0.05 < 0.01 < 0.01 < 0.01 <0.01 < 0.01
Parameters against which percentages were figured are given in Methods section.
b Values are the means sD, except for aluminum content and marrow fibrosis.
Statistical comparisons are for group I vs. group 2, by the U test of Mann-Whitney.
grating eyepiece II at a magnification of x 160 for "volume" and
x250 for "surface" data. For each sample, at least two
nonconsecutive sections were measured over the whole trabec-
ular space. The following parameters were measured or calcu-
lated : bone volume was figured as the percent of spongiosa
volume composed of mineralized and nonmineralized bone
matrix; total osteoid volume, as the percent of spongiosa
volume composed of osteoid tissue; relative osteoid volume, as
the percent of bone volume composed of osteoid tissue; osteoid
surface, as the percent of trabecular surface lined by osteoid
tissue; mean osteoid seam thickness, as the total osteoid
volume divided by the absolute value of osteoid surface,
obtained by calibrating the eyepiece graticule, for objective
x25, with a stage micrometer; and mineralization front, as the
percent of osteoid surface showing orthochromatic granules at
the limit between calcified and noncalcified matrix on toluidine
blue or eosine-azur stained sections. These stains show the
histochemical changes that occur in the organic matrix at the
site of active mineral deposition, where bone-seeking isotopes
and tetracyclines are fixed [19, 20]. The mineralization rate,
which also depends on the rate of matrix synthesis, is not
available with this method. Osteoblast surface was figured as
the percent of trabecular surface covered by well-developed
osteoblasts; osteoclast surface, as the percent of trabecular
surface covered by osteoclasts; and marrow fibrosis, as the
percent of spongiosa volume occupied by fibrous tissue, The
results obtained were compared with the normal values report-
ed by Bordier et al [21] for the extent of the mineralization
front, and with those reported by Schenk, Merz, and Muller
[22], and by Merz and Schenk [23, 241 for all the other
parameters.
Analytic microscopy. Two methods of analytic microscopy
have been used simultaneously: electron-probe X-ray micro-
analysis (MS 46 Cameca) and analytical ion microscopy (IMS
300 Cameca). Semithin epon or methacrylate sections obtained
with an LKB Ultrotome III microtome were used in both cases.
For electron microprobe, the sections were mounted on a
terphane slide and carbon-coated. With this method, the ele-
ments are detected by their X-ray characteristic emission under
an electron-beam bombardment. The images of distribution of a
given element are obtained by a scanning procedure. For ion
microscopy, the sections were mounted on a silver support,
With this method, the elements are characterized by mass
spectrometry: the sample surface is sputtered by a primary
beam of accelerated ions (Ofl; the secondary ions emitted from
the surface of the section are sorted according to their mass-
charge ratio [25—27]. The analytic images are obtained directly
on the screen or the photographic plate without any scanning
procedure. The resolution and sensitivity of the ion images
obtained by this method are much better than those of scanning
X-ray images. This new microanalytic method has recently
been applied to hard tissues [28, 291.
Statistical methods. Comparison of groups was made using
the nonparametric U test of Mann-Whitney [301.
Aluminum localization in uremic bone 379
Fig. 1. a Light micrograph from a bone section of patient 6. The calcified tissue (C) is surrounded by osteoid (0) (Toluidine blue, x200). b
Aluminum distribution shown by X-ray microanalysis on the same area as in panel a (serial section). Aluminum (white arrow) is localized at the
limit between calcified tissue and osteoid (x 200). cCalcium distribution shown by ion microscopy on the lower trabecula seen in panel a (serial sec-
tion, x400). d Aluminum distribution shown by ion microscopy on the same section as in panel c. Aluminum (white arrov.') is clearly localized at the
limit between calcified and noncalcified matrix.
Results
The two groups of patients have been differentiated on the
basis of the mineralization front, which was below 50% in all
cases of group l, and above 50% in all cases of group 2.
Bone histology (Table 2). In all patients of group I, the limit
between mineralized and nonmineralized matrix was deeply
scalloped, sharp, and no blurred areas were seen. The bone
tissue was predominantly of the lamellar type. The osteocytic
aspect was almost normal. In no case were metachromatic or
blurred areas seen around lacunae. Relative osteoid volume,
osteoid surface, and the mean osteoid seam thickness were
significantly higher in this group. The number of active bone
cells, osteoblasts, and osteoclasts, as well as the extent of
marrow fibrosis, were significantly lower.
Bone aluminum content (Table 2). Difference was not found
between the two groups in bone aluminum content. It was
above normal in all patients of group 1 and in all but one patient
of group 2. In group 1, bone aluminum content positively
correlated (r = 0.83; P < 0.01) with total osteoid volume. This
correlation was not observed in group 2. In neither group did
bone aluminum correlate with the other histologic parameters,
plasma biochemical data, or the duration of the dialysis period.
Bone aluminum localization. In the bone samples of group 1
patients, aluminum-dense lines were detected at the limit be-
tween the mineralized and the nonmineralized matrix. This
localization was observed by electron microprobe (Figs. 1 and
2), as well as by ion microscopy (Figs. 1, 2, and 3). In some
cases, aluminum-dense zones were also seen deep in the
calcified tissue. On serial sections, these zones were identified
as cement lines. In the bone samples of group 2 patients,
analytic microscopy detected a specific aluminum localization
only in the two patients with high bone aluminum content
(patients 12 and 13). In these patients, aluminum was mainly
seen along cement lines inside the calcified matrix (Fig. 4). In a
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FIg. 2. Aluminum localization in bone biopsies of patient 9, before (panels a and b) and after 5 months therapy (panels ctod) with 25-(OU)E13. a
Light micrograph. Osteoid tissue (0) is seen in the upper left and the lower right side of the image (toluidine blue, x200). b X-ray image of
aluminum (serial section). Aluminum (white arrow) is localized at the junction between mineralized and nonmineralized bone matrix. c Light
micrograph (toluidine blue, '<400). d Ion image of aluminum (serial section). 25-(Ol-l)D3 treatment did not change aluminum localization (white
arrow).
few sections, aluminum was also observed between osteoid and
calcified tissue. No aluminum could be localized in all the other
patients of this group.
Plasma biochemistry (Table 3). Plasma aluminum concentra-
tion was significantly higher in group 1. Plasma aluminum was
not correlated with the other biochemical parameters or with
the morphometric data in either group. Plasma iPTH concentra-
tion was significantly decreased in group 1. The mean plasma
calcium and phosphorus concentrations, plasma alkaline phos-
phatase activities, and plasma 25-(OH)D concentrations were
similar in patients of both groups.
Vitamin D therapy (Tables 1, 2, 4). In patients of group I
previously given vitamin D active derivatives, no relation could
be found between therapy and histology. Their bone lesions
could not be distinguished from those of the patients who had
never been treated. In three patients, the effect of 25-(0H)D3
and/or lcx-(OH)D3 therapy was evaluated by repeated bone
biopsies (Table 4). These treatments did not improve the
osteomalacic lesions; hypercalcemia easily developed. Bone
aluminum content and bone aluminum localization (Fig. 2) were
not changed by 25-(OH)D3 therapy.
Discussion
The present data strongly suggest that, in bone from uremic
patients, aluminum can interfere with normal mineralization.
This is supported by the observation that, in the bone tissue of a
group of osteomalacic uremic subjects who have been exposed
to aluminum-containing dialysis fluid, aluminum was preferen-
tially localized at the junction of mineralized bone and osteoid
tissue, the site where the bone mineral is normally first deposit-
ed. In these patients, the bone aluminum content significantly
correlated with total osteoid volume. Furthermore, the factors
— t
'C
p
'I
0I,
Aluminum localization in uremic bone 381
Fig. 3. Analytical microscopy of a bone section of patient 1. a Light micrograph. Osteoid tissue (0) and calcified tissue (C) (toluidine blue, x400). b
Ion image for calcium (serial section). c Ion image for aluminum on the same section as in panel b. Aluminum (white arrow) is concentrated
between calcified and noncalcified tissue.
known to be involved in the development of osteomalacia [1—41
could not account for the bone disease of these patients. There
was no evidence for chronic calcium or phosphate depletion.
With regard to vitamin D deficiency, plasma 25-(OH)-D concen-
trations were in the normal range in all but two patients. In
addition, long-term therapy with 25-(OH)D3, at doses which are
effective in curing azotemic osteomalacia due to a lack of the
active vitamin D metabolites [31, 32], failed to prevent or to
improve the osteomalacic lesions. Nor was lcs-(OH)D3 effec-
tive. Yet, at the dosage used, la(OH)-D3 was active, because it
provoked hypercalcemia.
The osteomalacic patients of the present study are similar to
those described by Coburn et al [33]. Their uremic patients had
histologic osteomalacia, which did not improve after 1,25-
(OH)2D3 or la-(OH)D3 therapy. Their plasma iPTH levels were
almost normal, and there was no evidence of phosphate deple-
tion. Hypercalcemia rapidly developed during treatment. Simi-
lar patients were also described by Ellis et al [34]. Aluminum
concentrations were not investigated, however, in these stud-
ies.
For comparison, a second group of uremic patients, with no
histologic mineralization defect but moderate to severe osteitis
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Fig. 4. Aluminum localization in bone tissue of patient 12. a to c Light micrographs. Cement lines (—*) are clearly seen inside the calcified tissue (C)
and osteoid seams (0) on the upper and lower surface of the trabeculae (toluidine blue, x400). b to d Aluminum distribution shown by ion
microscopy (serial sections). Aluminum (white arrow) is concentrated on cement lines and, in some regions, at the limit between osteoid (0) and
calcified tissue (C).
fibrosa, was studied by the same methods. Although, in these
patients, the plasma aluminum concentrations were significant-
ly lower than they were in the osteomalacic patients, their bone
aluminum content was not significantly different. In the patients
of both groups, the main source of aluminum was the water
used for dialysate preparation. Although the water was treated
by a "softener," it is known that this does not remove
aluminum. But, the aluminum contained in antacids and ab-
sorbed from the gut tract may also have contributed to the
intoxication. This is clearly suggested in the case of patient 18,
who was the only one to use deionization for dialysate prepara-
tion during the 9 years she underwent hemodialysis. In spite of
an almost complete lack of aluminum in the dialysate, her bone
aluminum content was above normal.
In most patients of the second group, aluminum could not be
localized in a specific area. In these cases, aluminum was
probably distributed diffusely throughout the tissue. Only in the
two patients with extremely elevated bone aluminum concen-
trations could aluminum be localized: it was mainly inside the
calcified matrix, along the cement lines. Cement lines separate
two bone layers of different ages, and outline the previous
resorption cavities. These lines contain neither cells nor colla-
gen fibers, but are mainly formed by matrix proteoglycans. It
has been shown that calcium [35], phosphorus, magnesium,
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Table 3. Plasma biochemistry of the two groups of patients before bone biopsy
Calciumb Alkaline
Aluminuma mmolesl Phosphonjsb phosphatasec iPTH 25-(OH)D
Patient no. rig/liter liter mmoles/liter lU/liter ng/ml ng/ml
Group I
570 (660) 2.47 0.05 1.86 0.34 138 1.65 8
2 155 (310) 2.81 0.15 2.05 0.26 245 0.32 17
3 250 (560) 2.51 0.15 1.2 0.21 (+) 1.7 31
4 90(800) 2.56 0.19 2.33 0.35 N 0.10 12
5 210 (235) 2.62 0.13 1.90 0.21 146 0.2 43
6 120 (200) 2.6 0.15 2.38 0.46 N 0.15 32
7 576 (405) 2.55 0.08 2.05 0.47 N 0.37 7
8 130 2.75 0.06 2.73 0.05 357 0.34 15
9 200 (335) 2.54 0.19 1.53 0.36 108 0.2 14
10 355 (500) 2.68 0.16 2.61 0.47 149 0.80 10
11 30 2.91 2.22 196 0.37 52
Group 2
12 160 (400) 2.45 0.13 2.24 0.41 199 — —
13 80 (185) 2.64 1.37 107 2.6 47
14 80 2.85 0.17 1.99 0.15 1155 4.6 10
15 90 2.40 0.01 1.87 0.33 372 1.4 15
16 27 2.57 0.04 2.63 0.47 228 2.4 5
17 40 2.14 0.06 1.31 0.36 1342 2.6 —
18 55 2.81 0.10 1.54 0.29 155 1.35 5
19 160 2.28 0.05 1.62 0.21 ++ — 29
20 40(200) 2.52 1.61 117 — —
21 65 2.12 0.08 1.79 0.40 ++ 1.45 5
Normal values <10 2.25 to 2.62 0.81 to 1.45 <220 <0.5 10 to 30
Pd <0.01 NS NS NS <0.01 NS
Values in parentheses indicate the highest aluminum concentrations measured during the months preceding the bone biopsy.
b Mean SD during the 6 months preceding the bone biopsy.
N is normal; (+), 50% increase; ++, 200% increase.
d Statistical comparisons are for group I vs. group 2, by the Mann-Whitney Ii test.
Table 4. Therapeutic effect of 25-(OH)D3 and la-(OH)D3 on three patients with severe osteomalacia
Therapy Morphometry
25-(OH)D3 lci-(OH)D3 Osteoid volume Mean
seam Osteo- Osteo-
Dura- Dura- Bone Bone Osteoid Mineraliza- thick- blast clast Marrow Plasma
Patient Dosage tion Dosage tion Al volume Relative Total surface tion front ness surface surface fibrosis 25-(OH)D
no. p.g/day mo rig/day mo ig/g % % % % % i % % % nglml
2
— — — — — 24.1 19.2 4.6 20.1 13.4 15.6 0.16 0.2 0
50 4 Ito 0.3 12 130 37.9 27 10.3 — 13.9 — — (+) —
—
17
40—75 23 — — 56.5 20.6 19.8 4 69.5 4 16 0 0.18 0
25—40 9 — — 57 24.5 20.6 5 76.3 4 23 0.3 0.16 0 43—
25—50 14 — — 84 44.9 21.3 9.6 80.8 12.6 19.4 0 0.7 0 14
9 50 5 — — 90 35.7 23.3 8.3 83 9 16.1 0 0.3 0 32
25—0 5 — — — 36.1 17.6 6.4 66.6 27 15.3 0 0 0 8
a Parameters against which percentages were figured are given in Methods section.
fluorine, potassium, and sodium can be concentrated on cement
lines [36], as is the case for aluminum. The mechanism by which
these elements are concentrated on cement lines is not known.
It is certainly different from the cell-mediated active process
that occurs along the calcification front. These elements, and
particularly aluminum, could not have been deposited on ce-
ment lines before the matrix synthesis and mineralization
commenced, because 45calcium and tetracyclines do not con-
centrate in these regions [19, 20].
From these results it appears that, to completely block the
mineralization process as has occurred in group I patients,
some factor(s) in addition to aluminum deposition in bone tissue
may be necessary. The question arises as to why, in one
patients group, aluminum is mainly localized along the mineral-
ization front and osteomalacia develops, whereas in the other
group, aluminum is diffuse or mainly observed on cement lines,
and the mineralization is normal. It appears that, as a group,
those patients with osteomalacia had a significantly lower
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plasma iPTH concentration, and significantly lower osteoclast
surface and marrow fibrosis than those who accumulated
aluminum but did not develop osteomalacia. This suggests that
in aluminum-intoxicated patients, secondary hyperparathyroid-
ism may in some way prevent the aluminum-induced mineral-
ization defect. The present study cannot explain the mechanism
for this possible relation between PTH and the bone lesions
related to aluminum intoxication. It has recently been reported
that PTH can influence aluminum metabolism. Plasma alumi-
num concentration rapidly decreases after parathyroidectomy
[371. In aluminum-intoxicated animals, PTH increases the alu-
minum concentration of the bone [38], as well as of the whole
body [39]. But in similar experimental studies, we could not
detect osteomalacia (unpublished observations).
It is also noteworthy that, although in patients of both groups,
plasma aluminum was above normal, it was significantly higher
in the osteomalacic patients. Because in most of these patients,
the number of active bone cells was reduced, a direct influence
of aluminum on bone cells cannot be excluded. In fact, in vitro
results obtained in our laboratory, indicate that aluminum does
act directly on bone cell activity, evaluated b acid and alkaline
phosphatase contents. In this experimental model, high alumi-
num concentrations also decrease the stimulating action of PTH
on bone phosphatases [401.
The present data and these observations support the hypothe-
sis of the action of aluminum on bone cells and matrix mineral-
ization, possibly modulated by PTH. The mechanism of these
interactions between PTH and aluminum merits further investi-
gation.
Acknowledgments
Preliminary results of this study have been reported at the IIImt
Workshop Bone Histomorphometry, Elkhorn at Sun Valley, Idaho,
May 28 to June 2, 1980, and at the VII Eur Cong Electron Microscopy,
The Hague, Netherlands, August 24—29, 1980. Analytical microscopy
studies were funded by CNRS and INSERM. J. Fritsch, R. Grimberg,
and F. Prouillet gave technical assistance.
Reprint requests to Dr. G. Cournot-Witmer, Laboratoire des Tissus
Calciflés, Tour Technique 6ème, Hôpital des Enfants Malades, /49, rue
de Sèvres, 75730 Paris Cedex 15, France
References
I. STANBURY SW: The role of vitamin D in renal bone disease. C/in
Endocrinol 7 (suppl):25S—30S, 1977
2. BAKERLRI, ACKRILL P, CATTELL WR, STAMP TCB, WATSON L:
latrogenic osteomalacia and myopathy due to phosphate depletion.
Br MedJ 3:150—152, 1974
3. Kooi- SW, FRASER D, REILLY BJ, HAMILTON JR, GALL DG, BELL
L: Rickets due to calcium deficiency. NEnglJMed297:1264—1266,
1977
4. PETTIFOR JM, Ross FP, MOODLEY G, DELUCA HF, TRAVERS R,
GLORIEUX FH: Calcium deficiency rickets associated with elevated
1,25 dihydroxyvitamin D concentrations in a rural black popula-
tion, in Vitamin D: Basic Research and Its Clinical Application,
edited by NORMAN AW, GRIGOLEIT HG, COBURN JW, DELUCA
HF, MAWER EB, SUDA T, Berlin, New-York, Walter de Gruyter,
1979, p. 1125
5. PLATTS MM, GOODE GC, HISLOP JS: Composition of the domestic
water supply and the incidence of fractures and encephalopathy in
patients on home dialysis. Br Med J 2:657—660, 1977
6. WARD MK, FEEST TG, ELLIS HA, PARKINSON IS, KERR DNS:
Osteomalacic dialysis osteodystrophy: Evidence for a water-borne
aetiological agent, probably aluminium. Lancet 1:841—845, 1978
7. PARKINSON IS, WARD MK, FEEST TG, FAWCETT RWP, KERR
DNS: Fracturing dialysis osteodystrophy and dialysis encephalop-
athy. Lancet 1:406—409, 1979
8. ALFREY AC, LEGENDRE GR, KAEI-INY WD: The dialysis encepha-
lopathy syndrome: Possible aluminum intoxication. N Eng! J Med
294:184—188, 1976
9. PARSONS V, DAVIES C, GOODE C, OGG C, SIDDIQUI J: Aluminium
in bone from patients with renal failure. Br Med J 4:273—275, 1971
10. RECKER RR, BLOTCKY AJ, LEFFLER JA, RACK EP: Evidence for
aluminum absorption from the gastrointestinal tract and bone
deposition by aluminum carbonate ingestion with normal renal
function. J Lab C/in Med 90:810—815, 1977
11. ALFREY AC, HEGG A, MILLER N, BERL T, BERN5 A: Interrelation-
ship between calcium and aluminum metabolism in dialysed uremic
patients. Mineral Electrolyte Metab 2:81—87, 1979
12. MARSDEN SNE, PARKINSON IS, WARD MK, ELLIS HA, KERR
DNS: Evidence for aluminium accumulation in renal failure. Proc
EDTA 16:588—596, 1979
13. ELLIS HA, MCCARTHY JH, HERRINGTON J: Bone aluminium in
haemodialysed patients and in rats injected with aluminium chlo-
ride: Relationship to impaired bone mineralization. J C/in Pathol
32:832—844, 1979
14. MAHURKAR SD, MEYERS L JR. COHEN J, KAMATH RV, DUNEA G:
Electroencephalographic and radionuclide studies in dialysis de-
mentia. Kidney mt 13:306—315, 1978
15. MATHIEU M, BRETAUDIERE JP, GALTEAU MM, GUIDOLLET J,
LALEGERIE P. BAILLY M, BURET P, DORCHE C, LoulsoT P,
SCHIELE F: Recommandations pour Ia mesure de l'activité cata-
lytique des phosphatases alcalines dans Ic serum humain. Ann Biol
Clin 35:271—273, 1977
16. ARNAUD CD, TSAO HS, LITTLEDIKE T: Radioimmunoassay of
human parathyroid hormone in serum. J C/in Invest 50:21—34, 1971
17. PREECE MA, O'RIORDAN JLH, LAWSON DEM, Koo
competitive protein-binding assay for 25-hydroxychL
and 25-hydroxyergocalciferol in serum. Clin Chim A
242, 1974
18. RANISTEANO-BOURDON 5, PROUILLET F, BOURDON R: Dosage de
l'aluminium et du gallium dans les liquides biologiques. Ann Biol
Clin 36:39—44, 1978
19. PONLOT R: Le Radiocalcium dans /'Etude de lOs. Bruxelles,
Arsnia SA, 1960
20. HARRIS WH, JACKSON RH, JOWSEY J: The in vivo distribution of
tetracyclines in canine bone. J Bone Joint Surg 44A:1308—l320,
1962
21. BORDIER P, ZINGRAFF J, GUERIS J, JUNGERS P, MARIE P, PECHET
M, RASMUSSEN H: The effect of la(OH)D3 and Ia,25(OH)2D3 on
the bone in patients with renal osteodystrophy. Am J Med 64:101—
107, 1978
22. SCHENK RK, MEItz WA, MULLER J: A quantitative histological
study on bone resorption in human cancellous bone. Acta Anar
74:44—53, 1969
23. MERZ WA, SCHENK RK: A quantitative histological study on bone
formation in human cancellous bone. Acta Anat 76:1—IS, 1970
24. MERZ WA, SCHENK RK: Quantitative structural analysis of human
cancellous bone. Ada Anat 75:54—66, 1970
25. SLODZIAN G: Etude d'une méthode d'analyse locale chimique et
isotopique utilisant l'émission ionique secondaire. Ann Phys 9:59 1—
648, 1964
26. GALLE P: Sur une nouvelle méthode d'analyse cellulaire utilisant Ic
phénomène d'émission ionique secondaire. Ann Phys Biol Med
4:84—94, 1970
27. GALLE P, BERRY JP, LEFEVRE R: Microanalysis in biology and
medicine: A review of results obtained with three microanalytical
methods, in Scanning E/ectron Microscopy Inc. edited by I0HARI
0, Illinois, AMF O'Hare, 1979, vol 2, p 703
28. LEFEVRE R, FRANCK RM, VOEGEL JC: The study of human dentine
with secondary ion microscopy and electron diffraction. Calcif
Tissue Res 19:251—261, 1976
29. QUINTANA C, QUETTIER A, SANDOZ D: Localization of mineral
elements in normal and strontium intoxicated Quail eggshell by
secondary ion mass spectroscopy and electron probe microanaly-
siS. CalcifTissue In! 30:151—161, 1976
30. SCHWARTZ D: Méthodes Statistiques a /'Usage des Médecins et
Biologistes. Paris, Flammarion, 1963
Aluminum localization in uremic bone 385
31. TEITELBAUM SL, BONE JM, STEIN PM, GILDEN GO, BATES M,
BOISSEAU VC, AvioLl LV: Calcifediol in chronic renal insufficien-
cy: Skeletal response. JAMA 235:164—167, 1976
32. WITMER G, MARGOLIS A, FONTAINE 0, FRITSCH J, LENOIR0,
BROYER M, BALSAN S: Effects of 25-hydroxycholecalciferol on
bone lesions of children with terminal renal failure. Kidney mt
10:395—408, 1976
33. COBURN JW, BRICKMAN AS, SHERRARD DJ, SINGER FR, WONG
EGC, BAYLINK DJ, NORMAN AW: Use of l,25(OH)2-vitamin D3 to
separate "types" of renal osteodystrophy. Proc EDTA 14:442—450,
1977
34. ELLIS HA, PIERIDES AM, FEEST TG, WARD MK, KERR DNS:
Histopathology of renal osteodystrophy with particular reference to
the effects of la-hydroxyvitamin D3 in patients treated by long-term
haemodialysis. Clin Endocrinol 7 (suppl):315—38S, 1977
35. SMITH JW: Age changes in the organic fraction of bone. J Bone
Joint Surg 45B:761—769, 1963
36. GALLE P. LEFEVRE R: Secondary ion emission microanalysis:
Biomedical applications. Microscopica Acta Suppl 2:341—354, 1978
37. ZINGRAFF J, COURNOT-WITMER 0, DRUEKE T, CHKOUFF N,
BOURDON R: Parathyroid hormone, aluminium and dialysis bone
disease, in, AbsiXVI Congr EDTA, Amsterdam, 1979, p 107
38. MAYOR OH, KEISER JA, MAKDANI D, Ku PK: Aluminum absorp-
tion and distribution: Effect of parathyroid hormone. Science
197:1187—1189, 1977
39. MAYOR OH, SPRAGUE JM, HOURANI MR, SANCHEZ TV: Parathy-
roid hormone mediated aluminum deposition and egress in the rat.
Kidney mt 17:40—44, 1980
40. LIEBERHERR M. GROSSE B, COURNOT-WITMER 0, THILCL,
BALSAN S: In vitro effects of aluminum on bone phosphatases: A
possible interaction with bPTH and vitamin D3 metabolites. Calqf
Tiss ml, in press, 1981
